It was found to display p53-independent tumor-selective activity in vitro, in leukemia patients’ blasts ex vivo and in mouse xenografts in vivo by acting directly on tumor cells, inducing TRAIL-dependent and ROS-mediated apoptosis and displaying favorable pharmacokinetics and tumor targeting [18]. The gene discussed is TNFSF10; the disease is neoplasm.